First Time Loading...
M

Metagenomi Inc
NASDAQ:MGX

Watchlist Manager
Metagenomi Inc
NASDAQ:MGX
Watchlist
Price: 7.08 USD 4.12% Market Closed
Updated: May 16, 2024

Intrinsic Value

MGX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Metagenomi Inc is a US-based company operating in Biotechnology industry. [ Read More ]

The intrinsic value of one MGX stock under the Base Case scenario is 4.97 USD. Compared to the current market price of 7.08 USD, Metagenomi Inc is Overvalued by 30%.

Key Points:
MGX Intrinsic Value
Base Case
4.97 USD
Overvaluation 30%
Intrinsic Value
Price
M
Worst Case
Base Case
Best Case

Valuation Backtest
Metagenomi Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MGX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Metagenomi Inc

Provide an overview of the primary business activities
of Metagenomi Inc.

What unique competitive advantages
does Metagenomi Inc hold over its rivals?

What risks and challenges
does Metagenomi Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Metagenomi Inc.

Provide P/S
for Metagenomi Inc.

Provide P/E
for Metagenomi Inc.

Provide P/OCF
for Metagenomi Inc.

Provide P/FCFE
for Metagenomi Inc.

Provide P/B
for Metagenomi Inc.

Provide EV/S
for Metagenomi Inc.

Provide EV/GP
for Metagenomi Inc.

Provide EV/EBITDA
for Metagenomi Inc.

Provide EV/EBIT
for Metagenomi Inc.

Provide EV/OCF
for Metagenomi Inc.

Provide EV/FCFF
for Metagenomi Inc.

Provide EV/IC
for Metagenomi Inc.

Show me price targets
for Metagenomi Inc made by professional analysts.

What are the Revenue projections
for Metagenomi Inc?

How accurate were the past Revenue estimates
for Metagenomi Inc?

What are the Net Income projections
for Metagenomi Inc?

How accurate were the past Net Income estimates
for Metagenomi Inc?

What are the EPS projections
for Metagenomi Inc?

How accurate were the past EPS estimates
for Metagenomi Inc?

What are the EBIT projections
for Metagenomi Inc?

How accurate were the past EBIT estimates
for Metagenomi Inc?

Compare the revenue forecasts
for Metagenomi Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Metagenomi Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Metagenomi Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Metagenomi Inc compared to its peers.

Compare the P/E ratios
of Metagenomi Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Metagenomi Inc with its peers.

Analyze the financial leverage
of Metagenomi Inc compared to its main competitors.

Show all profitability ratios
for Metagenomi Inc.

Provide ROE
for Metagenomi Inc.

Provide ROA
for Metagenomi Inc.

Provide ROIC
for Metagenomi Inc.

Provide ROCE
for Metagenomi Inc.

Provide Gross Margin
for Metagenomi Inc.

Provide Operating Margin
for Metagenomi Inc.

Provide Net Margin
for Metagenomi Inc.

Provide FCF Margin
for Metagenomi Inc.

Show all solvency ratios
for Metagenomi Inc.

Provide D/E Ratio
for Metagenomi Inc.

Provide D/A Ratio
for Metagenomi Inc.

Provide Interest Coverage Ratio
for Metagenomi Inc.

Provide Altman Z-Score Ratio
for Metagenomi Inc.

Provide Quick Ratio
for Metagenomi Inc.

Provide Current Ratio
for Metagenomi Inc.

Provide Cash Ratio
for Metagenomi Inc.

What is the historical Revenue growth
over the last 5 years for Metagenomi Inc?

What is the historical Net Income growth
over the last 5 years for Metagenomi Inc?

What is the current Free Cash Flow
of Metagenomi Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Metagenomi Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Metagenomi Inc

Current Assets 278.3m
Cash & Short-Term Investments 271.2m
Receivables 2.5m
Other Current Assets 4.6m
Non-Current Assets 86.6m
Long-Term Investments 10.7m
PP&E 65.2m
Other Non-Current Assets 10.7m
Current Liabilities 68.9m
Accounts Payable 1.8m
Accrued Liabilities 14.9m
Other Current Liabilities 52.2m
Non-Current Liabilities 80.8m
Other Non-Current Liabilities 80.8m
Efficiency

Earnings Waterfall
Metagenomi Inc

Revenue
44.8m USD
Operating Expenses
-123.2m USD
Operating Income
-78.5m USD
Other Expenses
10.2m USD
Net Income
-68.3m USD

Free Cash Flow Analysis
Metagenomi Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

MGX Profitability Score
Profitability Due Diligence

Metagenomi Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

Negative Revenue Growth Forecast
Negative Operating Income
Negative Net Income
Negative ROE
18/100
Profitability
Score

Metagenomi Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

MGX Solvency Score
Solvency Due Diligence

Metagenomi Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
57/100
Solvency
Score

Metagenomi Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MGX Price Targets Summary
Metagenomi Inc

Wall Street analysts forecast MGX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MGX is 19.58 USD with a low forecast of 10.1 USD and a high forecast of 26.25 USD.

Lowest
Price Target
10.1 USD
43% Upside
Average
Price Target
19.58 USD
177% Upside
Highest
Price Target
26.25 USD
271% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Competitors Analysis
Metagenomi Inc

Shareholder Return

MGX Price
Metagenomi Inc

1M 1M
-14%
6M 6M
-53%
1Y 1Y
-53%
3Y 3Y
-53%
5Y 5Y
-53%
10Y 10Y
-53%
Annual Price Range
7.08
52w Low
6.17
52w High
15
Price Metrics
Average Annual Return
N/A
Standard Deviation of Annual Returns
N/A
Max Drawdown -59%
Shares Statistics
Market Capitalization 265.7m USD
Shares Outstanding 37 530 000
Percentage of Shares Shorted
N/A

MGX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Metagenomi Inc

Country

United States of America

Industry

Biotechnology

Market Cap

265.7m USD

Dividend Yield

0%

Description

Metagenomi Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Emeryville, California and currently employs 223 full-time employees. The company went IPO on 2024-02-09. Metagenomi, Inc. is a precision genetic medicine company. The firm is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). The company has also developed an expansive and modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. Its platform enables it to rapidly and effectively find, screen, and select tools with the highest targetability, specificity, and efficiency in order to develop them into genetic medicine.

Contact

CALIFORNIA
Emeryville
5959 Horton St, Floor 7
+15108714880
https://metagenomi.co/

IPO

2024-02-09

Employees

223

Officers

Co-Founder, CEO & Chairman of the Board
Dr. Brian Charles Thomas Ph.D.
President, COO & Director
Dr. Jian Irish M.B.A., Ph.D.
Chief Medical Officer
Dr. Sarah B. Noonberg M.D., Ph.D.
Co-Founder & Member of Scientific Advisory Board
Dr. Jak Knowles M.D.
Chief Financial Officer
Ms. Pamela M. Wapnick M.B.A.
Chief Scientific Officer
Dr. Luis G. Borges Ph.D.
Show More
Vice President of Corporate Legal, Compliance & Corporate Secretary
Mr. Matthew L. Wein J.D.
Senior Vice President of Preclinical
Dr. Alan Brooks Ph.D.
Head of Discovery
Dr. Christopher Brown
Show Less

See Also

Discover More
What is the Intrinsic Value of one MGX stock?

The intrinsic value of one MGX stock under the Base Case scenario is 4.97 USD.

Is MGX stock undervalued or overvalued?

Compared to the current market price of 7.08 USD, Metagenomi Inc is Overvalued by 30%.